Theriva Biologics, Inc.
Here’s whether Theriva Biologics, Inc. (TOVX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); 50-day MA is rising (+4.72% over 10 days); RSI 47 — healthy momentum range; 3-month momentum positive (+57.5%); rising volume confirms the move (2.59x 30d avg). Concerns: below the 50-day MA (medium-term momentum negative); weak 1-year return of -39.2%. Currently 64.8% off its 52-week high. Score: +4/7.
TOVX is holding above its long-term 200-day MA ($0.28) but has slipped below the 50-day MA ($0.31), pointing to short-term weakness in an otherwise intact trend. An RSI of 47.3 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -39.2% compares to +22.9% for SPY (trailed the market by 62.0%). The current 64.8% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.